<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000580268"><TermName>recombinant human interleukin-11</TermName><TermPronunciation>(ree-KOM-bih-nunt HYOO-mun in-ter-LOO-kin...)</TermPronunciation><TermDefinition><DefinitionText>A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Recombinant human interleukin-11 is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory.  It is a type of biological response modifier.  Also called Neumega, oprelvekin,  and rhIL-11.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720700" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;recombinant human interleukin-11&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720701" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;interleucina-11 humana recombinada&quot;" language="es" id="_4"/><SpanishTermName>interleucina-11 humana recombinada</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para aumentar el número de células sanguíneas, especialmente plaquetas, en algunos pacientes de cáncer que reciben quimioterapia. La interleucina-11 humana recombinada es una forma de la interleucina-11 (una citocina normalmente elaborada por las células de sostén de la médula ósea) que se produce en el laboratorio. Es un tipo de modificador de la respuesta biológica.  También se llama Neumega, oprelvecina,  y rhIL-11.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-10-03</DateFirstPublished><DateLastModified>2009-03-25</DateLastModified></GlossaryTerm>
